| Characteristics . | All patients (N = 325) . | Patients with stroke (n = 25) . | Patients without stroke (n = 300) . | P-value . |
|---|---|---|---|---|
| Age at AAV diagnosis, years, mean (s.d.) | 64.6 (16.3) | 67 (12.5) | 64 (17) | 0.34 |
| Female, n (%) | 152 (47) | 141 (47) | 11 (44) | 0.77 |
| GPA, MPA and EGPA diagnosis, n | 169, 134, 22 | 16, 8, 1 | 153, 126, 21 | 0.44 |
| PR3-ANCA positivea, n (%) | 158 (52) | 11 (48) | 147 (52) | 0.70 |
| MPO-ANCA positiveb, n (%) | 138 (45) | 13 (52) | 125 (44) | 0.45 |
| Organ involvement at AAV diagnosis, n (%) | ||||
| General | 247 (76) | 19 (76) | 228 (76) | 1.00 |
| Cutaneous | 28 (9) | 2 (8) | 26 (9) | 0.90 |
| Mucous membranes/eyes | 24 (7) | 3 (12) | 21 (7) | 0.35 |
| ENT | 149 (46) | 14 (56) | 135 (45) | 0.28 |
| Cardiovascular | 15 (5) | 0 0 | 15 (5) | 0.61 |
| Abdominal | 18 (6) | 0 0 | 15 (6) | 0.39 |
| Chest | 164 (51) | 16 (64) | 148 (49) | 0.15 |
| Renal | 218 (67) | 15 (60) | 203 (68) | 0.43 |
| Nervous system | 36 (11) | 5 (20) | 31 (10) | 0.13 |
| Laboratory data at diagnosis | ||||
| S-creatinine, μmol/l, median (IQR) | 134 (74–304) | 115 (80–410) | 135 (73–293) | 0.68 |
| Haemoglobin, g/l, mean (s.d.) | 110 (19) | 111 (20) | 110 (19) | 0.76 |
| White blood cell count, × 109, mean (s.d.) | 13 (4.9) | 15 (4.9) | 13 (5) | 0.25 |
| Platelet count, × 109/l, mean (s.d.) | 372 (145) | 419 (182) | 367 (141) | 0.09 |
| CRP, mg/l, median (IQR) | 79 (23–134) | 99 (26–36) | 77 (22–135) | 0.71 |
| ESR, mm/h, mean (s.d.) | 64 (33) | 61 (42) | 64 (33) | 0.75 |
| BVAS at diagnosis, mean (s.d.) | 15 (6) | 16 (7) | 15 (6) | 0.14 |
| VDI at 12 months, median (IQR) | 1 (0–2) | 2 (0-3) | 1 (0-2) | 0.34 |
| ESKD, n (%) | 51 (16) | 5 (20) | 46 (15) | 0.53 |
| Deaths, n (%) | 143 (44) | 13 (52) | 130 (43) | 0.40 |
| Characteristics . | All patients (N = 325) . | Patients with stroke (n = 25) . | Patients without stroke (n = 300) . | P-value . |
|---|---|---|---|---|
| Age at AAV diagnosis, years, mean (s.d.) | 64.6 (16.3) | 67 (12.5) | 64 (17) | 0.34 |
| Female, n (%) | 152 (47) | 141 (47) | 11 (44) | 0.77 |
| GPA, MPA and EGPA diagnosis, n | 169, 134, 22 | 16, 8, 1 | 153, 126, 21 | 0.44 |
| PR3-ANCA positivea, n (%) | 158 (52) | 11 (48) | 147 (52) | 0.70 |
| MPO-ANCA positiveb, n (%) | 138 (45) | 13 (52) | 125 (44) | 0.45 |
| Organ involvement at AAV diagnosis, n (%) | ||||
| General | 247 (76) | 19 (76) | 228 (76) | 1.00 |
| Cutaneous | 28 (9) | 2 (8) | 26 (9) | 0.90 |
| Mucous membranes/eyes | 24 (7) | 3 (12) | 21 (7) | 0.35 |
| ENT | 149 (46) | 14 (56) | 135 (45) | 0.28 |
| Cardiovascular | 15 (5) | 0 0 | 15 (5) | 0.61 |
| Abdominal | 18 (6) | 0 0 | 15 (6) | 0.39 |
| Chest | 164 (51) | 16 (64) | 148 (49) | 0.15 |
| Renal | 218 (67) | 15 (60) | 203 (68) | 0.43 |
| Nervous system | 36 (11) | 5 (20) | 31 (10) | 0.13 |
| Laboratory data at diagnosis | ||||
| S-creatinine, μmol/l, median (IQR) | 134 (74–304) | 115 (80–410) | 135 (73–293) | 0.68 |
| Haemoglobin, g/l, mean (s.d.) | 110 (19) | 111 (20) | 110 (19) | 0.76 |
| White blood cell count, × 109, mean (s.d.) | 13 (4.9) | 15 (4.9) | 13 (5) | 0.25 |
| Platelet count, × 109/l, mean (s.d.) | 372 (145) | 419 (182) | 367 (141) | 0.09 |
| CRP, mg/l, median (IQR) | 79 (23–134) | 99 (26–36) | 77 (22–135) | 0.71 |
| ESR, mm/h, mean (s.d.) | 64 (33) | 61 (42) | 64 (33) | 0.75 |
| BVAS at diagnosis, mean (s.d.) | 15 (6) | 16 (7) | 15 (6) | 0.14 |
| VDI at 12 months, median (IQR) | 1 (0–2) | 2 (0-3) | 1 (0-2) | 0.34 |
| ESKD, n (%) | 51 (16) | 5 (20) | 46 (15) | 0.53 |
| Deaths, n (%) | 143 (44) | 13 (52) | 130 (43) | 0.40 |
Results available for 308 patients.
Results available for 309 patients.
AAV: ANCA-associated vasculitis; GPA: granulomatosis with polyangiitis; MPA: microscopic polyangiitis; EGPA: eosinophil granulomatosis with polyangiitis; PR3: proteinase 3; MPO: myeloperoxidase; SD: standard deviation; ENT: ear-nose-throat; IQR: interquartile range; CRP: c-reactive protein; ESR: erythrocyte sedimentation rate; BVAS: Birmingham Vasculitis Activity Score; VDI: vasculitis damage index; ESKD: end stage kidney disease.
| Characteristics . | All patients (N = 325) . | Patients with stroke (n = 25) . | Patients without stroke (n = 300) . | P-value . |
|---|---|---|---|---|
| Age at AAV diagnosis, years, mean (s.d.) | 64.6 (16.3) | 67 (12.5) | 64 (17) | 0.34 |
| Female, n (%) | 152 (47) | 141 (47) | 11 (44) | 0.77 |
| GPA, MPA and EGPA diagnosis, n | 169, 134, 22 | 16, 8, 1 | 153, 126, 21 | 0.44 |
| PR3-ANCA positivea, n (%) | 158 (52) | 11 (48) | 147 (52) | 0.70 |
| MPO-ANCA positiveb, n (%) | 138 (45) | 13 (52) | 125 (44) | 0.45 |
| Organ involvement at AAV diagnosis, n (%) | ||||
| General | 247 (76) | 19 (76) | 228 (76) | 1.00 |
| Cutaneous | 28 (9) | 2 (8) | 26 (9) | 0.90 |
| Mucous membranes/eyes | 24 (7) | 3 (12) | 21 (7) | 0.35 |
| ENT | 149 (46) | 14 (56) | 135 (45) | 0.28 |
| Cardiovascular | 15 (5) | 0 0 | 15 (5) | 0.61 |
| Abdominal | 18 (6) | 0 0 | 15 (6) | 0.39 |
| Chest | 164 (51) | 16 (64) | 148 (49) | 0.15 |
| Renal | 218 (67) | 15 (60) | 203 (68) | 0.43 |
| Nervous system | 36 (11) | 5 (20) | 31 (10) | 0.13 |
| Laboratory data at diagnosis | ||||
| S-creatinine, μmol/l, median (IQR) | 134 (74–304) | 115 (80–410) | 135 (73–293) | 0.68 |
| Haemoglobin, g/l, mean (s.d.) | 110 (19) | 111 (20) | 110 (19) | 0.76 |
| White blood cell count, × 109, mean (s.d.) | 13 (4.9) | 15 (4.9) | 13 (5) | 0.25 |
| Platelet count, × 109/l, mean (s.d.) | 372 (145) | 419 (182) | 367 (141) | 0.09 |
| CRP, mg/l, median (IQR) | 79 (23–134) | 99 (26–36) | 77 (22–135) | 0.71 |
| ESR, mm/h, mean (s.d.) | 64 (33) | 61 (42) | 64 (33) | 0.75 |
| BVAS at diagnosis, mean (s.d.) | 15 (6) | 16 (7) | 15 (6) | 0.14 |
| VDI at 12 months, median (IQR) | 1 (0–2) | 2 (0-3) | 1 (0-2) | 0.34 |
| ESKD, n (%) | 51 (16) | 5 (20) | 46 (15) | 0.53 |
| Deaths, n (%) | 143 (44) | 13 (52) | 130 (43) | 0.40 |
| Characteristics . | All patients (N = 325) . | Patients with stroke (n = 25) . | Patients without stroke (n = 300) . | P-value . |
|---|---|---|---|---|
| Age at AAV diagnosis, years, mean (s.d.) | 64.6 (16.3) | 67 (12.5) | 64 (17) | 0.34 |
| Female, n (%) | 152 (47) | 141 (47) | 11 (44) | 0.77 |
| GPA, MPA and EGPA diagnosis, n | 169, 134, 22 | 16, 8, 1 | 153, 126, 21 | 0.44 |
| PR3-ANCA positivea, n (%) | 158 (52) | 11 (48) | 147 (52) | 0.70 |
| MPO-ANCA positiveb, n (%) | 138 (45) | 13 (52) | 125 (44) | 0.45 |
| Organ involvement at AAV diagnosis, n (%) | ||||
| General | 247 (76) | 19 (76) | 228 (76) | 1.00 |
| Cutaneous | 28 (9) | 2 (8) | 26 (9) | 0.90 |
| Mucous membranes/eyes | 24 (7) | 3 (12) | 21 (7) | 0.35 |
| ENT | 149 (46) | 14 (56) | 135 (45) | 0.28 |
| Cardiovascular | 15 (5) | 0 0 | 15 (5) | 0.61 |
| Abdominal | 18 (6) | 0 0 | 15 (6) | 0.39 |
| Chest | 164 (51) | 16 (64) | 148 (49) | 0.15 |
| Renal | 218 (67) | 15 (60) | 203 (68) | 0.43 |
| Nervous system | 36 (11) | 5 (20) | 31 (10) | 0.13 |
| Laboratory data at diagnosis | ||||
| S-creatinine, μmol/l, median (IQR) | 134 (74–304) | 115 (80–410) | 135 (73–293) | 0.68 |
| Haemoglobin, g/l, mean (s.d.) | 110 (19) | 111 (20) | 110 (19) | 0.76 |
| White blood cell count, × 109, mean (s.d.) | 13 (4.9) | 15 (4.9) | 13 (5) | 0.25 |
| Platelet count, × 109/l, mean (s.d.) | 372 (145) | 419 (182) | 367 (141) | 0.09 |
| CRP, mg/l, median (IQR) | 79 (23–134) | 99 (26–36) | 77 (22–135) | 0.71 |
| ESR, mm/h, mean (s.d.) | 64 (33) | 61 (42) | 64 (33) | 0.75 |
| BVAS at diagnosis, mean (s.d.) | 15 (6) | 16 (7) | 15 (6) | 0.14 |
| VDI at 12 months, median (IQR) | 1 (0–2) | 2 (0-3) | 1 (0-2) | 0.34 |
| ESKD, n (%) | 51 (16) | 5 (20) | 46 (15) | 0.53 |
| Deaths, n (%) | 143 (44) | 13 (52) | 130 (43) | 0.40 |
Results available for 308 patients.
Results available for 309 patients.
AAV: ANCA-associated vasculitis; GPA: granulomatosis with polyangiitis; MPA: microscopic polyangiitis; EGPA: eosinophil granulomatosis with polyangiitis; PR3: proteinase 3; MPO: myeloperoxidase; SD: standard deviation; ENT: ear-nose-throat; IQR: interquartile range; CRP: c-reactive protein; ESR: erythrocyte sedimentation rate; BVAS: Birmingham Vasculitis Activity Score; VDI: vasculitis damage index; ESKD: end stage kidney disease.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
